The Sotagliflozin in Patients With Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF) trial was the first study demonstrating that SGLT2 inhibitors may diminish cardiovascular events in individuals with both HFpEF and T2DM [29]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.